Logo

Indications - Healing of Erosive Esophagitis: Dexlansoprazole is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks. Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn for up to 6 months. Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlansoprazole is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.

Dosage & Administration - Dosage Dexlansoprazole dosing recommendations- Maintenance of Healed erosive esophagitis and relief of heartburn: 30 mg Once daily Symptomatic Non-Erosive GERD: 30 mg Once daily for 4 weeks Healing of erosive esophagitis: 60 mg Once daily for up to 8 weeks Administration Dexlansoprazole can be taken without regard to food. It should be swallowed whole. Alternatively, Dexlansoprazole capsules can be administered as follows: Open capsule Sprinkle intact granules on one tablespoon Swallow immediately. Granules should not be chewed. If a capsule is missed at its usual time, it should be taken as soon as possible. But if it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.

Side Effects - Common side effects: Diarrhea, abdominal pain, nausea, vomiting & flatulence.

Contraindications - Dexlansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.

Others - Pregnancy & Lactation Pregnancy Category B. There is no adequate and well-controlled studies with Dexlansoprazole in pregnant women. There is no adequate and well-controlled studies with Dexlansoprazole in Lactating mother. Precautions & Warnings Gastric Malignancy, Clostridium difficile Associated Diarrhea, Bone fracture, Hypomagnesemia, and concomitant use of Dexlansoprazole with Methotrexate. Use in Special Populations Use in children & adolescents: Safety and effectiveness of Dexlansoprazole in patients below 12 years age have not been established. Geriatric use: No dose adjustment is necessary for elderly patients. Renal impairment: No dose adjustment of Dexlansoprazole is necessary for patients with renal impairment. Hepatic impairment: No dose adjustment for Dexlansoprazole is necessary for patients with mild hepatic impairment. A maximum daily dose of Dexlansoprazole 30 mg should be considered for patients with moderate hepatic impairment. Overdose Effects There have been no reports of a significant overdose of Dexlansoprazole. Multiple doses of Dexlansoprazole 120 mg and a single dose of Dexlansoprazole 300 mg did not result in death or other severe adverse events.